Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 13/20 | 0.53 |
| ▸ | GRM5 | P41594 | 11/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 4/20 | 0.35 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2888911 | 0.84 | GRM1 (0.76) | GRM1GRM5 | |
| SCHEMBL2893262 | 0.81 | GRM1 (0.73) | GRM1GRM5ALDH1A1SMN1; SMN2NAMPT | |
| SCHEMBL2893240 | 0.80 | GRM1 (0.71) | GRM1GRM5ALDH1A1SMN1; SMN2 | |
| SCHEMBL2892949 | 0.79 | GRM1 (0.51) | GRM1GRM5ALDH1A1SMN1; SMN2NAMPT | |
| SCHEMBL2888969 | 0.77 | GRM1 (0.72) | GRM1GRM5ALDH1A1SMN1; SMN2 | |
| SCHEMBL2896111 | 0.76 | GRM1 (0.52) | GRM1GRM5ALDH1A1SMN1; SMN2 | |
| SCHEMBL2893797 | 0.75 | GRM1 (0.58) | GRM1GRM5ALDH1A1SMN1; SMN2 | |
| SCHEMBL2892061 | 0.75 | GRM1 (0.74) | GRM1GRM5ALDH1A1SMN1; SMN2 | |
| SCHEMBL2891168 | 0.74 | GRM1 (0.72) | GRM1GRM5ALDH1A1SMN1; SMN2 | |
| SCHEMBL2885105 | 0.73 | GRM1 (0.73) | GRM1GRM5ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858800-B2 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20070191389-A1 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| CN-1980901-A | Biaryl derivatives | BANYU PHARMA CO LTD (JP) | 2007-06-13 | — | — | CN | disclosed |
| EP-1764362-A1 | BIARYL DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-21 | — | — | EP | disclosed |
| EP-1764362-A1 | BIARYL DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191389-A1 | Biaryl derivatives | GRM1, GRIN1, GRIN2B | GRM1 1/4885GRM5 26/4885ALDH1A1 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.